Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
Yan Leyfman/LinkedIn
Apr 14, 2026, 13:09

Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology

Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn:

”Thank you to Cancer Network for the feature.

Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease

Gene editing has moved from concept to clinic.

By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing Sickle Cell Disease – we’re aiming to rewrite its biology.

Targeting regulators like BCL11A is elegant.

Making it durable, scalable, and accessible is the real challenge.

This is where curative intent becomes tangible.

Worth the read if you’re following where ‘hematology and gene therapy’ is heading.”

Stay updated with Hemostasis Today.

Cancer Network CRISPR Gene therapy Health Hematology Hemoglobin Hemostasis Hemostasis News Hemostasis Today Medicine SCD Sickle Cell Disease Yan Leyfman
NewsFeed